In clinical practice, the presence of these polymorphisms is associated with the development of diseases such as cancer, diabetes, and coronary disease, in which an altered HIF-1α is observed in various groups among different populations [30–32]. This evidence concerns the gene HIF1A and diabetes mellitus.